ADC Therapeutics SA Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
ADC Therapeutics SA (ADCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 455.97 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-13
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 408.16K shares, a 950.16% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 47.81K shares, a 30.17% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 92.23K shares, a 677.56% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 227.03K shares, a 150.84% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 394.86K shares, a 59.25% decline from fiscal 2024.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 968.96K shares, a 2.66% increase from fiscal 2023.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 943.82K shares, a 235.49% increase from fiscal 2022.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 281.32K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 408.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 455.97K shares 10-Q · filed 2026-08-13 | 548.21K shares derived: sum of 3 quarters · filed 2026-08-13 | 775.23K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 47.81K shares 10-Q · filed 2026-05-04 | 140.05K shares derived: sum of 2 quarters · filed 2026-05-04 | 367.07K shares derived: sum of 3 quarters · filed 2026-05-04 | 405.94K shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 92.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 319.26K shares derived: sum of 2 quarters · filed 2026-03-10 | 358.13K shares derived: sum of 3 quarters · filed 2026-03-10 | 394.86K shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 227.03K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 265.89K shares derived: sum of 2 quarters · filed 2025-11-10 | 302.63K shares 10-Q · filed 2025-11-10 | 314.49K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 38.87K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 75.60K shares 10-Q · filed 2025-08-12 | 87.46K shares derived: sum of 3 quarters · filed 2025-08-12 | 177.97K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 36.73K shares 10-Q · filed 2025-05-14 | 48.59K shares derived: sum of 2 quarters · filed 2025-05-14 | 139.10K shares derived: sum of 3 quarters · filed 2025-05-14 | 997.81K shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 11.86K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 102.37K shares derived: sum of 2 quarters · filed 2025-03-27 | 961.08K shares derived: sum of 3 quarters · filed 2025-03-27 | 968.96K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 90.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 949.22K shares derived: sum of 2 quarters · filed 2024-11-07 | 957.10K shares 10-Q · filed 2024-11-07 | |
| 2024-06-30 | 858.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 866.60K shares 10-Q · filed 2024-08-06 | ||
| 2024-03-31 | 7.89K shares 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | 943.82K shares 10-K · filed 2025-03-27 | |||
| 2022-12-31 | 281.32K shares 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |